Kiadis Pharma B.V. , a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Health Canada for its new clinical study with ATIR .
http://www.b3cnewswire.com/20130226845/kiadis-pharma-receives-regulatory-approval-from-health-canada-for-a-phase-ii-clinical-study-with-its-blood-cancer-treatment-atir-tm.html
http://www.b3cnewswire.com/20130226845/kiadis-pharma-receives-regulatory-approval-from-health-canada-for-a-phase-ii-clinical-study-with-its-blood-cancer-treatment-atir-tm.html
No comments:
Post a Comment